Gerresheimer is adding 3,500 square meters to its medical plastics facility in Horsovsky Tyn, Czech Republic, at a cost of about €18 million, adding to a previously announced expansion at the site. According to the company, it will hire approximately 200 more personnel over the next two years to handle increased production of inhalers and other devices at the site. … [Read more...] about Gerresheimer adds inhaler manufacturing capability in the Czech Republic
News
Hi-Tech Pharmacal attributes sales increase to nasal sprays
Hi-Tech Pharmacal has reported a 10% increase in net sales of generic products for the quarter ended April 30, 2012 compared to the same quarter in 2011, an increase due primarily to a sales increase for fluticasone proprionate nasal spray. According to the company, sales of fluticasone propionate nasal spray were up from $26.9 million in the same period last year to … [Read more...] about Hi-Tech Pharmacal attributes sales increase to nasal sprays
DPT Labs acquired by Renaissance
Renaissance Acquisition Holdings has acquired Texas-based CDMO DPT Laboratories, which offers MDI and nasal spray testing and manufacturing. DPT has facilities in San Antonio, TX and Lakewood, NJ. According to the company, the management team and business will continue as before. DPT President and COO Paul Johnson commented, “Renaissance and its management team … [Read more...] about DPT Labs acquired by Renaissance
Cipla hires Frank Pieters to head respiratory business
Indian pharmaceutical company Cipla has hired former Teva vice-president Frank Pieters as Head of European Business and Head of Global Respiratory Business. Pieters was most recently Senior VP for the Region of Southern Europe at Teva. Cipla manufactures a wide range of inhaled medications. A recent article in the Business Standard quotes Cipla CFO S Radhakrishnan … [Read more...] about Cipla hires Frank Pieters to head respiratory business
Prosonix and Imperial College London to collaborate on inhaled drugs
Prosonix and Imperial College London have signed an agreement to collaborate on development of inhaled therapies based on multi-component particles (MCPs) manufactured using Prosonix's proprietary particle engineering technology. The company will coordinate with Dr. Omar Usmani of the college's National Heart and Lung Institute (NHLI) to perform in vivo and in vitro … [Read more...] about Prosonix and Imperial College London to collaborate on inhaled drugs
Results from four Phase 3 studies of GSK’s LAMA/LABA inhaler for COPD
GlaxoSmithKline and Theravance have announced results from four Phase 3 studies of its umeclidinium bromide (UMEC)/vilanterol (VI) combination DPI for the treatment of COPD. The studies include two 24-week efficacy studies and two 24-week active comparator studies comparing UMEC/VI with tiotropium. UMEC is a a long-acting muscarinic antagonist (LAMA) and vilanterol is … [Read more...] about Results from four Phase 3 studies of GSK’s LAMA/LABA inhaler for COPD
European approval for flutiform
The European Commission (EC) has approved SkyePharma's flutiform fluticasone propionate/formoterol fumarate MDI for the treatment of asthma in the 21 European countries using the decentralized procedure. The CHMP issued a positive opinion for flutiform in April 2012 after the 21 member states had failed to reach a consensus in late 2011. The company says that it … [Read more...] about European approval for flutiform
EPAG recommends further investigation of low volume cascade impaction for DPIs
A study by the European Pharmaceutical Aerosol Group (EPAG) titled "Effect of Sampling Volume on Dry Powder Inhaler (DPI)-Emitted Aerosol Aerodynamic Particle Size Distributions (APSDs) Measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen Eight-Stage Cascade Impactor (ACI)" and published on June 8, 2012 by AAPS PharmSciTech finds that reduced … [Read more...] about EPAG recommends further investigation of low volume cascade impaction for DPIs
Insmed gets $20 million loan
According to Insmed Incorporated, the company has entered into a loan agreement with Hercules Technology Growth Capital that will allow it to access up to $20 million for continued development of Arikace inhaled liposomal amikacin. Hercules received a warrant to purchase 329,932 shares of Insmed common stock at $2.94 per share as part of the agreement. Insmed … [Read more...] about Insmed gets $20 million loan
CHMP issues positive recommendation for Seebri Breezhaler
According to Novartis, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Seebri Breezhaler glycopyrronium/NVA237 DPI for the treatment of COPD. Novartis submitted the MAA in September 2011. "This positive opinion for Seebri Breezhaler is a major milestone in our efforts to offer COPD patients and … [Read more...] about CHMP issues positive recommendation for Seebri Breezhaler